ArticleMedical science monitor : international medical journal of experimental and clinical research2015
Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Common polymorphisms in CD44 gene and susceptibility to cancer: A systematic review and meta-analysis of 45 studies.Oncotarget · 2016Pooled it
- Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis.Oncotarget · 2016Pooled it
- Significance ofInternational journal of medical sciences · 2024Article
- CD44 rs13347C>T Variants in 3'UTR and Prostate Neoplasms: A Case-control Study and Bioinformatics Approach.International journal of molecular and cellular medicine · 2023Article
- Mutant Allele of CD44 (rs8193C>T) and Pum2 Regulatory Element as A Prognosis Factor of Prostate Neoplasms: A Case-Control and In Silico Studies.Cell journal · 2022Article
- Clinical risk factors of carbohydrate antigen-125, cytokeratin fragment 19, and neuron-specific enolase in liver metastases from elderly lung cancer patients.Frontiers in genetics · 2022Article
- Article
- Article
- Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.Frontiers in oncology · 2021Review
- Article
- Effect ofAmerican journal of translational research · 2020Article
- Article
- Article
- Association of CD44 polymorphisms and susceptibility to HBV-related hepatocellular carcinoma in the Chinese population.Journal of clinical laboratory analysis · 2019Article
- [Risk Factors of Non-small Cell Lung Cancer with Bone Metastasis after Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Article
- CD44 promotes cell proliferation in non-small cell lung cancer.Oncology letters · 2018Article
- Adverse prognostic impact ofOncoTargets and therapy · 2017Article
- Associations of five polymorphisms in the CD44 gene with cancer susceptibility in Asians.Scientific reports · 2016Article
- Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses.Oncotarget · 2016Article
- Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC. MATERIAL AND
methodsA total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.
resultsCD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20-0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50-4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34-0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31-0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05-2.21, P=0.027).
conclusionsCD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.